The Immunomodulatory Effect of Sugammadex After Total Hip Replacement Surgery Under Neuraxial Anaesthesia: a Pilot Study (MAGIC)
Innate Inflammatory Response, Osteoarthritis, Hip
About this trial
This is an interventional treatment trial for Innate Inflammatory Response
Eligibility Criteria
Inclusion Criteria: Age of 18 years or older Scheduled for total hip replacement surgery under neuraxial anesthesia Scheduled for primary hip replacement surgery Informed consent obtained Exclusion Criteria: Insufficient control of the Dutch language to read the patient information and to fill out the questionnaires Mentally incapacitated patients Known or suspected hypersensitivity to sugammadex Deficiency of vitamin K dependent clotting factors or coagulopathy Severe renal disease (creatinine clearance <30 ml/min), including patients on dialysis) Severe liver disease (Child-Pugh Classification C) Women who are or may be pregnant or currently breastfeeding Women of childbearing potential who don't use adequate method of contraception Severe vertebral column disorder Chronic use of psychotropic drugs Known hypertrophic obstructive cardiomyopathy, severe aortic valve stenosis or severe mitral valve stenosis Chronic use of NSAID's, steroids or immunosuppressive drugs
Sites / Locations
- RadboudumcRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Sugammadex
Placebo
Sugammadex administration at the end of surgery
Placebo administration at the end of surgery